TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated liposarcoma patients treated with an HDM2 antagoni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andrea Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. de Jonge, Madelyn Light, Steve Rowley, Sandrine Macé, James Watters
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/260fdcaadef641d3801dbcc9cba2ac83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:260fdcaadef641d3801dbcc9cba2ac83
record_format	dspace
spelling	oai:doaj.org-article:260fdcaadef641d3801dbcc9cba2ac832021-12-02T14:38:36ZTP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma10.1038/ncomms126092041-1723https://doaj.org/article/260fdcaadef641d3801dbcc9cba2ac832016-08-01T00:00:00Zhttps://doi.org/10.1038/ncomms12609https://doaj.org/toc/2041-1723Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated liposarcoma patients treated with an HDM2 antagonist.Joonil JungJoon Sang LeeMark A. DicksonGary K. SchwartzAxel Le CesneAndrea VargaRastilav BahledaAndrew J. WagnerEdwin ChoyMaja J. de JongeMadelyn LightSteve RowleySandrine MacéJames WattersNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-7 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Joonil Jung Joon Sang Lee Mark A. Dickson Gary K. Schwartz Axel Le Cesne Andrea Varga Rastilav Bahleda Andrew J. Wagner Edwin Choy Maja J. de Jonge Madelyn Light Steve Rowley Sandrine Macé James Watters TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
description	Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated liposarcoma patients treated with an HDM2 antagonist.
format	article
author	Joonil Jung Joon Sang Lee Mark A. Dickson Gary K. Schwartz Axel Le Cesne Andrea Varga Rastilav Bahleda Andrew J. Wagner Edwin Choy Maja J. de Jonge Madelyn Light Steve Rowley Sandrine Macé James Watters
author_facet	Joonil Jung Joon Sang Lee Mark A. Dickson Gary K. Schwartz Axel Le Cesne Andrea Varga Rastilav Bahleda Andrew J. Wagner Edwin Choy Maja J. de Jonge Madelyn Light Steve Rowley Sandrine Macé James Watters
author_sort	Joonil Jung
title	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
title_short	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
title_full	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
title_fullStr	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
title_full_unstemmed	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
title_sort	tp53 mutations emerge with hdm2 inhibitor sar405838 treatment in de-differentiated liposarcoma
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/260fdcaadef641d3801dbcc9cba2ac83
work_keys_str_mv	AT jooniljung tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT joonsanglee tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT markadickson tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT garykschwartz tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT axellecesne tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT andreavarga tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT rastilavbahleda tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT andrewjwagner tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT edwinchoy tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT majajdejonge tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT madelynlight tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT steverowley tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT sandrinemace tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma AT jameswatters tp53mutationsemergewithhdm2inhibitorsar405838treatmentindedifferentiatedliposarcoma
_version_	1718390939928494080

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Ejemplares similares